If you can't charge "hundreds of thousands" of dollars a year for drugs, will there be drugs for orphan diseases? » Read More
After Valeant took a bite out of Bill Ackman's hedge fund, the billionaire described his firm's standing to CNBC's Scott Wapner.
GlaxoSmithKline said its CEO Andrew Witty would retire in 12 months, prompting Britain's biggest drugmaker to start a formal search for his successor.
Creditors of Valeant Pharmaceuticals are beginning to demand new terms that could further pressure the drugmaker's business model, sources said.
Michael Bell, global market strategist at JP Morgan, discusses investing in pharma and biotech.
Access, diagnostics and the quality of cancer care are challenges in developing countries, warns Dr Masum Hossain, APAC regional president and managing director of Pfizer Oncology.
Dr Masum Hossain, APAC regional president and managing director of Pfizer Oncology, explains why immunotherapy is a priority for the pharmaceutical firm, especially in Asia.
Longtime Fed and Valeant bear Jim Grant joined CNBC to discuss the pharma stock and the Fed's move on Wednesday.
The drug company's stock closed down 51% to $33.54 a share Tuesday on disappointing financial news, USA TODAY reports.
David Maris, Wells Fargo Securities, and CNBC's Meg Tirrell talk about Valeant Pharm's future.
CNBC's Meg Tirrell reports Valeant's stunning fall has left some smaller hedge funds vulnerable, and an number of investors feeling as though they have to ride it out and see what happens.
CNBC's Meg Tirrell reports on Valeant's wild ride as the stock plummeted and Moody's downgrades the company's debt. Also a look at which hedge funds lost billions of dollars in the rout.
Steve Brozak, managing partner and president at WBB Securities, said it's important to see if Valeant's business model can support its level of debt.
Andrew Left of Citron Research explains why Mallinckrodt is worse than Valeant. Mark Trudeau, Mallinckrodt CEO, responds.
Wall Street investor Bill Ackman says he is still confident in Valeant and he plans to be more proactive in his dealings with it.
GW Pharmaceuticals' CEO Justin Gover says this successful clinical trial for new drug Epidiolex is not only good for the company but also for cannabinoids in modern medicine. CNBC's Meg Tirrell reports.
GW Pharma's phase 3 study on its cannabinoid Epidiolex shows positive results for epilepsy, sending shares of the company higher, reports CNBC's Meg Tirrell.
"This is a way to get rid of a terrible, terrible drug, oxycodone," CNBC's Jim Cramer says.
CNBC's Meg Tirrell takes a look at where the presidential candidates stand on big pharma issues.
Kyle Bass, who started the Coalition for Affordable Drugs, has challenged a drug patent from biotech company Acorda, reports CNBC's Meg Tirrell.
Loncar Investments CEO, Brad Loncar says immunotherapy is the most innovative, high-growth area in the biotech space, while describing the company’s ETF.
Get the best of CNBC in your inbox